


Interim arrangement for Prescribing of Fiasp® during COVID-19 Pandemic

Fiasp® is a fast-acting insulin aspart formulation in which the addition of nicotinamide (vitamin B₃) results in a faster initial absorption of insulin compared to NovoRapid®. In mid Essex, this would be considered further down the line in Type 1 and 2 diabetes management if current strategies are not working and improvement in glycaemic control is needed. Treatment is initiated by Tier 2 or secondary care and due to the risk of increased hypoglycaemic episodes, prescribing is usually retained by Tier 2 or secondary care until the patient is stabilised on treatment. However, with the Government guidance on social distancing, shielding and self-isolation to halt the spread of COVID-19, patients are being reviewed remotely and obtaining a prescription from the hospital defeats the purpose of social distancing. This interim arrangement has been put in place in order to ensure timely access to insulin treatment for patients and avoid unnecessary travel. This arrangement is applicable only to patients under the care the Children's Diabetes Team.



Contact:
 Children's Diabetes Team: mie-tr.BroomfieldCDT@nhs.net